RxDoctor Payments Data

Cindy Siu, MD

Family Medicine · Milford, DENPI 1346635943

Payments from drug & device makers

$1,879in general payments, 2019–2025

Across 57 payments — averaging $32.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$875
  • Novo Nordisk$412
  • Lilly USA, LLC$169
  • Pfizer$107
  • Astellas Pharma US Inc$73
  • Amgen$72
  • plus $172 from 5 others

What the payments were for

  • Food & beverage$1,83498%
  • Education$452%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,879 in reported general payments places this provider in the 75th percentile of 352 family medicine providers in Delaware.

See all family medicine providers in Delaware

Medicare billing

Part B allowed, 2024
$276,114
Medicare patients
581
Services billed
3,595

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide40$80,800
MounjaroTirzepatide32$57,019
JardianceEmpagliflozin43$55,319
TrulicityDulaglutide23$51,476
FarxigaDapagliflozin Propanediol33$41,268
MyrbetriqMirabegron27$34,841
EliquisApixaban32$30,077
Trelegy ElliptaFluticasone/Umeclidin/Vilanter16$15,990
Atorvastatin Calcium421$7,672
Rosuvastatin Calcium192$7,630
Breo ElliptaFluticasone/Vilanterol13$7,511
Arnuity ElliptaFluticasone Furoate16$6,968
TradjentaLinagliptin11$6,139
Levothyroxine Sodium380$4,117
Ezetimibe49$3,009

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$169$108,49555 claims
Novo NordiskOzempic$412$80,80040 claims
AstraZenecaFarxiga$875$41,26833 claims
Astellas Pharma US IncMyrbetriq$73$34,84127 claims
PfizerEliquis$107$30,07732 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 352 family medicine providers in Delaware.

Other family medicine in Milford

See the full list for Delaware

Where these figures come from

Is this you, or does something look wrong? →